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Abstract: Placental abruption (PA), a pregnancy-related vascular disorder, is a leading cause of maternal and peri-
natal morbidity and mortality. The success of identifying genetic susceptibility loci for PA, a multi-factorial heritable 
disorder, has been limited. We conducted a genome-wide association study (GWAS) and candidate gene asso-
ciation study using 470 PA cases and 473 controls from Lima, Peru. Genotyping for common genetic variations 
(single nucleotide polymorphisms, SNPs) was conducted using the Illumina Cardio-Metabo Chip platform. Common 
variations in 35 genes that participate in mitochondrial biogenesis (MB) and oxidative phosphorylation (OS) were 
selected for the candidate gene study. Regression models were fit to examine associations of each SNP with risk 
of PA. In pathway analyses, we examined functions and functional relationships of genes represented by the top 
GWAS hits. Genetic risk scores (GRS), based on top hits of the GWAS and candidate gene analyses, respectively, 
were computed using the risk allele counting method. The top hit in the GWAS analyses was rs1238566 (empirical 
P-value=1.04e-4 and FDR-adjusted P-value=5.65E-04) in FLI-1 gene, a megakaryocyte-specific transcription factor. 
Networks of genes involved in lipid metabolism and cell signaling were significantly enriched by the 51 genes whose 
SNPs were among the top 200 GWAS hits (P-value <2.1e-3). SNPs known to regulate MB (e.g. CAMK2B, NR1H3, 
PPARG, PRKCA, and THRB) and OP (e.g., COX5A, and NDUF family of genes) were associated with PA risk (P-value 
<0.05). GRS was significantly associated with PA risk (trend P-value <0.001 and 0.01 for GWAS and candidate gene 
based GRS, respectively). Our study suggests that integrating multiple analytical strategies in genetic association 
studies can provide opportunities for identifying genetic risk factors and novel molecular mechanisms that underlie 
PA.
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Introduction
Placental abruption (PA) is the separation of 
the placenta from the uterus prior to delivery of 
the fetus [1-3]. This pregnancy-related vascular 
disorder complicates about 1% of all births and 
is associated with significant complications in 
the mother and her offspring [1-3]. The success 
of identifying genetic susceptibility loci for PA, a 
multi-factorial heritable disorder, has been lim-
ited [4-13]. Findings from the only PA-related 
genome-wide association study (GWAS) from 
our team provided suggestive evidence sup-
porting associations of variations in maternal 
cardiometabolic genes with risk of PA. We previ-
ously identified variations in SNPs in novel 
(SMAD2 MIR17HG, and DGKB) and candidate 
(AGT, KDR, F2, and THBD) genes that may be 
associated with PA [14]. However, the previous 
GWAS study was conducted among 253 PA 
cases and 258 controls, limiting the study’s sta-
tistical power to identify significant associa-
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tions. The need to conduct larger PA-related 
GWAS studies and the opportunities they pro-
vide to investigate genetic variations in recently 
recognized molecular pathways that lead to PA, 
such as mitochondrial biogenesis and oxidative 
stress, motivated the current study.
Impaired placental function and oxidative phos-
phorylation, pathways implicated in the patho-
genesis of PA, have their origins extending to 
mitochondrial dysfunction [15, 16]. Mitochond- 
ria are semi-autonomous cytoplasmic organ-
elles of the eukaryotic system that produce 
adenosine triphosphate by the coupling of oxi-
dative phosphorylation to respiration, providing 
a major source of energy to the cell [15, 16]. 
Approximately 1,500 proteins encoded by 
nuclear DNA (nDNA) regulate mitochondrial bio-
genesis and maintain mitochondrial structure 
and function by regulating oxidative phosphory-
lation, apoptosis, and mitochondrial DNA repli-
cation, transcription, and translation [17]. While 
most previous work on genetic variations and 
mitochondrial dysfunction has focused on vari-
ations in mitochondrial DNA (mtDNA), recently, 
investigators have noted that single nucleotide 
polymorphisms (SNPs) in nDNA may be associ-
ated with mitochondrial dysfunction (and relat-
ed disease conditions) through subtle changes 
in encoded proteins that alter mitochondrial 
biogenesis and/or oxidative phosphorylation 
activity [18]. On the basis of this emerging lit-
erature and our recent observation that PA risk 
is associated with increased mtDNA copy num-
ber abundance [19], a marker of mitochondrial 
dysfunction, we hypothesized that variations in 
mitochondrial biogenesis- and oxidative phos-
phorylation-related genes are associated with 
PA risk.
The current study extends our previous GWAS 
study by doubling the size of study participants 
(470 PA cases and 473 controls), testing of spe-
cific hypothesis linking genetic variation in 
mitochondrial biogenesis and oxidative phos-
phorylation-related genes with PA risk, and 
employing multiple analytical approaches to 
investigate genetic risk factors of PA.
Methods
Study setting and study population
This study was conducted as part of the 
Peruvian Abruptio Placentae Epidemiology 
(PAPE) study. The study setting and study popu-
lation were described before [14]. Briefly, study 
participants were recruited and enrolled among 
women who were admitted for obstetrical ser-
vices to the Hospital Nacional Dos de Mayo, 
Instituto Especializado Materno Perinatal, and 
Hospital Madre-Niño San Bartolomé in Lima, 
Peru, between August 2002 and May 2004 and 
between September 2006 and September 
2008. 
Hospital admission and delivery logs were mon-
itored daily to identify PA cases among new 
admissions to antepartum, emergency room, 
and labor and delivery wards of participating 
hospitals. PA was diagnosed based on evi-
dence of retroplacental bleeding (fresh blood) 
entrapped between the decidua and the pla-
centa or blood clots behind the placenta and 
any two of the following: (i) vaginal bleeding in 
late pregnancy not due to placenta previa or 
cervical lesions; (ii) uterine tenderness and/or 
abdominal pain; (iii) fetal distress or death. 
Controls were selected from among pregnant 
women who delivered at participating hospitals 
during the study period and did not have a diag-
nosis of PA in the current pregnancy.
Institutional Review Boards of participating 
institutions approved the project protocol. All 
participants provided written informed conse- 
nt.
Data collection 
Trained research personnel conducted partici-
pant interviews using standardized structured 
questionnaires to collect information on socio-
demographic characteristics and risk factors 
including maternal age, marital status, employ-
ment status during pregnancy, medical history, 
and smoking and alcohol consumption (both 
before and during the current pregnancy). A 
brief physical examination was conducted to 
measure maternal height, weight, and mid-arm 
circumference. Medical records were reviewed 
to abstract information on course and out-
comes of the pregnancy [14]. Blood specimens 
collected from 470 PA cases and 473 controls 
were processed for assessment of genetic vari-
ation as described below.
DNA extraction and genotyping
The Gentra PureGene Cell kit for DNA prepara-
tions (Qiagen, Hilden, Germany) was used to 
extract DNA from blood specimens collected 
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from 470 PA cases and 473 controls. 
Genotyping to characterize genome-wide varia-
tion in cardiovascular and metabolism genes 
was conducted using the Illumina Cardio-
Metabochip (Illumina Inc, San Diego, CA) plat-
form [14]. Briefly, the Cardio-Metabo Chip is a 
high-density custom array that captures DNA 
variation at regions previously related to dis-
eases and traits relevant to metabolic and ath-
erosclerotic-cardiovascular endpoints using 
217,697 SNPs.
Data quality control and preprocessing
Rigorous quality control procedures were 
applied to the DNA before analyses [20]. 
Individuals were excluded (n=48) if they had 
genotyping failure for more than 10% of the 
sites. SNPs were excluded if the minor allele 
frequency was less than 1%, if the SNP failed to 
be genotyped in more than 10% of the study 
population, or if the SNP was not in Hardy-
Weinberg equilibrium among controls (critical 
P=0.0001). After these QC procedures, a total 
of 124,499 SNPs and 470 PA cases and 473 
controls remained for analyses. Population 
stratification was assessed using the genomic 
inflation factor [21] and adjustment for the first 
four principal components in regression mod-
els [22].
Candidate gene/SNP selection
A total of 35 genes that were involved in mito-
chondrial biogenesis and oxidative phosphory-
lation were selected based on literature 
(Supplementary Table 1). There were a total of 
322 SNPs representing these genes in the 
Cardio-Metabo Chip. Of these 322 SNPs, 310 
SNPs were excluded because they were rare 
(12 SNPs with MAF <1%) and/or in significant 
linkage disequilibrium (298 SNPs with R2 >0.8) 
with another SNP in the set. A total of 11 SNPs 
in 9 candidate genes remained for further 
analysis.
Statistical analyses
Logistic regression models were fit to evaluate 
associations between each SNP and risk of PA 
in both the genome-wide and candidate gene 
analyses. Bonferroni correction was used to 
account for multiple testing (P-value threshold 
0.05/124,499 SNPs=8.03e-6) in overall 
genome-wide level analyses. In addition to 
assessment of the empirical P-value, we also 
computed false discovery rate (FDR) for a less 
conservative assessment of statistical signifi-
cance [23]. For the secondary candidate SNP-
PA association analyses, we used P <0.05 as a 
cut-off to determine statistical significance.
Ingenuity Pathway Analyses (IPA, Ingenuity, 
Redwook, CA) was used to evaluate functions 
and functional relationships of genes repre-
sented by top 200 hits from our current PA 
GWAS analysis. In IPA, each gene identifier was 
mapped to its corresponding gene object in the 
Ingenuity Pathways Knowledge Base (IPKB). 
These genes were overlaid onto a global molec-
ular network developed from information con-
tained in the IPKB. Gene-enrichment of net-
works was assessed using network score 
based on a modified Fisher’s exact test. The 
network score, negative log of P-values of 
Fisher tests, was used to rank biological signifi-
cance of gene function networks in relation to 
PA.
Using risk allele counting method, we comput-
ed genetic risk scores (GRS) for top hits from 
the GWAS and candidate gene analyses [24]. 
The top 10-15 risk alleles that were common 
(higher MAF) and not in LD with other SNPs in 
the set were selected from each analysis. We 
assumed the additive genetic risk model cor-
responding to a linear increase of PA risk to the 
presence of 0, 1, and 2 risk alleles. In addition, 
we assumed equal risk of PA conferred by each 
locus. Participants were categorized into four 
groups defined by the 25th, 50th, and 75th per-
centile GRS scores among control participants 
(i.e., Group 1: 0-25%ile, Group 2: 25-50%ile, 
Group 3: 50-75%ile, and Group 4: 75-100%ile). 
Regression models were then fit to examine 
associations of the genetic score with PA risk 
using Group 1 (0-25%ile group) as a referent.
Statistical analyses were conducted using 
PLINK v1.07, SAS, and R software. Pathway 
analyses were conducted using IPA v6 software 
[25].
Results 
Selected socio-demographic and medical/
obstetric characteristics of participants are 
shown in Table 1. Average maternal age of PA 
cases and controls was 28 years. PA cases and 
controls were similar with respect to their fre-
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Table 1. Socio-demographic and reproductive character-








Maternal age at delivery, years* 27.7 (6.7) 27.7 (6.6)
    <35 380 (11.2) 388 (10.8)
    ≥35 90 (18.0) 85 (17.4)
Nulliparous 41 (8.4) 12 (2.41)
Less than High school education 353 (72.3) 356 (71.3)
Employed during pregnancy 213 (43.5) 223 (44.8)
Planned pregnancy 195 (40.5) 207 (42.2)
No prenatal vitamin 154 (31.6) 148 (29.7)
Smoked during pregnancy 18 (3.7) 9 (1.8)
Alcohol use during pregnancy 21 (4.2) 26 (5.3)
Pre-pregnancy BMI, kg/m2* 23.8 (3.8) 23.7 (3.9)
    <18.5 24 (5.3) 15 (3.1)
    18.5-24.9 288 (64.0) 322 (67.5)
    25.0-29.9 111 (24.7) 103 (21.6)
    ≥30.0 27 (6.0) 37 (7.8)
Chronic hypertension 22 (4.6) 12 (2.4)
Preeclampsia or Eclampsia 134 (27.9) 37 (7.4)
History of placental abruption 5 (1.1) 0 (0)
Infant birthweight, grams* 2430 (863) 3158 (690)
Gestational age at delivery, weeks* 35.4 (4.1) 38.3 (2.7)
*Mean (standard deviation), otherwise number (%).
quency of high school completion and employ-
ment during pregnancy. They also had compa-
rable mean pre-pregnancy BMI 
(average 24 kg/m2 for both). However, 
compared with controls, PA cases 
were more likely to be smokers dur-
ing pregnancy, and have a history of 
preeclampsia, eclampsia or PA. As 
expected, PA cases delivered low 
birth weight infants more frequently 
and had shorter gestational lengths, 
compared with controls.
We did not observe significant 
genomic inflation (λ=0.96) (Figure 1). 
In genome-wide analyses, none of 
the P-values for SNP-PA associations 
surpassed the stringent criteria for 
significant associations (Bonferroni 
corrected P-value 8.03e-6) (Figure 
2). FLI-1 gene (rs1238566, P-valu- 
e=1.04e-4, FDR=5.65e-4), a mega-
karyocyte-specific transcription fac-
tor, was the top hit in the GWAS anal-
yses. Genes represented by the top 
GWAS hits are shown in Table 2. A 
total of 51 genes were represented 
by the top 200 GWAS hits (with 
P-values <2.1e-3, FDR <2.0e-3); and, 
these were evaluated for functions 
and functional relationships using 
IPA. The top networks enriched by 
these genes included networks of 
lipid metabolism (score=40, P-valu- 
e=4.25e-18) and cell signaling 
(score=26, P-value=5.11e-12) (Table 
3 & Figure 3). In additional to these 
51 genes, the top networks included 
other well-described genes in lipid 
metabolism (e.g., FLI-1, CETP, LIPC, 
and THRB) and cell signaling (e.g., 
Akt, NFKB, and PI3K) (Figure 3). In 
candidate gene analyses, SNPs in 
genes related to mitochondrial bio-
genesis (e.g., CAMK2B, NR1H3, 
PPARG, PRKCA, and THRB) or oxida-
tive phosphorylation (e.g., COX5A, 
and NDUF family of genes) were sig-
nificantly associated with PA risk 
(P-values <0.05) (Table 4).
Two GRS were computed using 14 
SNPs identified in the GWAS analy-
ses and 11 SNPs in 9 genes identi-
fied in the candidate gene associa-
tion analyses, respectively (Supplementary 
Table 2). Both GRS were significantly associat-
Figure 1. Q-Q plot (λ=0.96). 
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Figure 2. Manhattan plot of genome-wide association study of placental abruption. 
Table 2. Top hits of analyses examining genome-wide genetic variations and placental abruption risk
Gene SNP Minor Allele MAF Odds Ratio Empirical P-value FDR
FLI1 rs1238566 G 0.34 1.46 (1.21-1.77) 1.05E-04 5.65E-04
C6orf108 rs7832 A 0.07 2.14 (1.48-3.18) 1.08E-04 5.65E-04
LOC647946 rs10502722 C 0.41 0.7 (0.59-0.85) 1.13E-04 5.65E-04
ZAR1L rs206136 G 0.11 0.56 (0.41-0.74) 1.19E-04 5.65E-04
CAP2 rs1320995 C 0.35 0.67 (0.56-0.83) 1.77E-04 5.65E-04
TECPR2 rs4900536 G 0.35 0.70 (0.57-0.83) 1.89E-04 5.65E-04
DPP6 rs2024366 G 0.14 1.65 (1.27-2.17) 2.97E-04 7.55E-04
PLIN3 rs3760950 A 0.38 1.42 (1.18-1.72) 3.74E-04 7.55E-04
CAP2 rs1320994 G 0.37 0.71 (0.58-0.85) 4.48E-04 7.55E-04
PSMD5 rs10760117 A 0.18 1.52 (1.18-1.88) 4.53E-04 7.55E-04
FRRS1 rs951125 G 0.21 0.67 (0.53-0.84) 4.59E-04 7.55E-04
NCOR2 rs12582168 G 0.43 0.72 (0.60-0.87) 4.77E-04 7.55E-04
EDIL3 rs350477 A 0.24 0.67 (0.55-0.86) 6.03E-04 7.76E-04
KIF16B rs8117456 C 0.22 1.48 (1.16-1.81) 6.71E-04 7.76E-04
CAP2 rs9383287 G 0.38 0.72 (0.59-0.86) 6.73E-04 7.76E-04
CETP rs891144 A 0.18 0.66 (0.51-0.83) 6.94E-04 7.76E-04
MYO5B rs17716496 C 0.17 0.66 (0.52-0.84) 7.04E-04 7.76E-04
KIF16B rs1028540 A 0.39 1.38 (1.15-1.66) 7.35E-04 7.76E-04
LOC253039 rs4837796 G 0.19 1.48 (1.16-1.83) 8.10E-04 8.10E-04
Abbreviations: MAF = Minor Allele Frequency in Controls.
ed with risk of PA (linear trend P-values <0.001 
and 0.01 for the genome-wide GRS and the 
candidate GRS, respectively) (Table 5). 
Participants in the highest GRS Group (Group 
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In candidate gene analysis, SNPs in genes par-
ticipating in mitochondrial biogenesis (e.g. 
CAMK2B, NR1H3, PPARG, PRKCA, and THRB) 
or oxidative phosphorylation (e.g., COX5A, and 
NDUF family of genes) were significantly associ-
ated with PA risk (P-values <0.05). GRS com-
puted using risk alleles identified from both the 
GWAS and candidate gene analyses were asso-
ciated with risk of PA.
Most previous studies of common genetic vari-
ations and risk of PA [26-30] were small candi-
4), GRS >17.1 in the GWAS analysis and GRS 
>10.0 in the candidate gene analysis, had 5.45 
(95% CI: 3.68-8.06) and 1.91 (95% CI: 1.20-
3.06) fold higher risk of PA, respectively, com-
pared with participants in the lowest GRS 
Group, Group 1 (GRS <10.9 in the GWAS analy-
sis and GRS <8.0 in the candidate gene analy-
sis) (Table 5).
Discussion
In genome-wide and candidate gene associa-
tion analyses, we identified several SN- 
Ps, genes, and path-
ways that are related 
to PA risk. In the 
GWAS analysis among 
PA cases and con-
trols, the top hit was 
rs1238566 (P-value 
=1.04e-4) in FLI-1 
gene. None of the 
SNPs reached statisti-
cal significance af- 
ter correction for mul-
tiple testing using the 
conservative Bonfer- 
roni correction. Netw- 
orks enriched by 51 
genes represented by 
the top 200 GWAS 
hits (P-values <2.1e-
3) included networks 
of lipid metabolism 
(e.g., FLI-1, CETP, LI- 
PC, and THRB) and 
cell signaling (e.g., 
Akt, NFKB, and PI3K). 
Table 3. SNPs in candidate genes and risk of placental abruption
Gene SNP Minor Allele MAF Odds Ratio Empirical P-value FDR
CAMK2B Chr7:44221559 G 0.27 0.77 (0.63-0.95) 0.01 0.02
NR1H3 Chr11:47237338 A 0.16 1.31 (1.02-1.68) 0.04 0.04
PPARG Chr3:12309555 A 0.16 1.44 (1.11-1.84) 0.005 0.02
PPARG Chr3:12336385 A 0.47 1.19 (0.99-1.44) 0.07 0.04
PPARG Chr3:12440243 A 0.18 1.30 (1.02-1.62) 0.03 0.04
PRKCA Chr17:61738444 G 0.29 0.82 (0.67-1.02) 0.06 0.04
THRB rs9814223 A 0.35 0.83 (0.68-0.99) 0.05 0.04
COX5A Chr15:73013139 G 0.14 0.76 (0.59-1.00) 0.05 0.04
NDUFA10 Rs4149549 A 0.21 1.23 (0.98-1.54) 0.07 0.04
NDUFA12 Rs11107847 A 0.43 0.83 (0.70-1.01) 0.05 0.04
NDUFC2 Rs627297 C 0.17 0.74 (0.59-0.95) 0.01 0.02
Abbreviations: MAF = Minor Allele Frequency in Controls.
Figure 3. Top network represented by genes represented by top hits of GWAS analysis. 
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Table 5. Genetic risk score (GRS) and risk of placental abruption











Intervals <10.9 10.9-13.9 14.0-17.0 ≥17.1
Cases, n (%) 49 (10) 45 (10) 140 (30) 236 (50)
Controls, n (%) 142 (30) 69 (15) 138 (29) 124 (26)
OR (95% CI)** 1.00 1.85 (1.12-3.05) 2.90 (1.97-4.33) 5.45 (3.68-8.06) <0.001
Candidate Gene Analysis
Intervals <8 8-8.9 9-9.9 ≥10
Cases, Number (%) 34 (8) 72 (17) 113 (27) 197 (47)
Controls, Number (%) 58 (14) 80 (19) 103 (25) 175 (42)
OR (95% CI)** 1.00 1.55 (0.91-2.64) 1.88 (1.14-3.11) 1.91 (1.20-3.06) 0.01
*GRS computed from 14 SNPs that are top hits from GWAS analyses, and 11 SNPs that are top hits from the candidate gene 
association analyses. **Odds ratios (and 95% confidence intervals) from logistic regression models adjusted for age, sex, and 
population admixture, linear trend P-values.
Table 4. Significant networks represented by top GWAS hits
Molecules in Network Score FocusMolecules (#) Top Functions P-value
26s Proteasome, ABLIM, Actin, Akt, CAP2, 
CETP, DAB1, DISC1, ERK1/2, FBXO41, FLI1, 
FSH, KCNH2, LDL, Lh, LIPC, LOC81691, 
MY058, NCOR2, NFKB, PARK2, PI3K, PLN3, 
Prl4a1, PSMD5, RASSF2, SAV1, SHC4, SIRT1, 
T3-Trbeta, THRB, Ubiquitin, Utp14b, Ybx1-ps3





AMICA1, BTN2A2, BTN3A1, BTN3A2, C12orf29, 
C6orf108, CC2D2A, DDX6OL, DPP6, EML2, 
FAM108B1, FSTL4, GABARAP, GSDMD, IFNG, 
KCTD7, KIF16B, LUZP1, MORC2, NLN, PHB, 
PHLDB2, PITPNC1, PLEKHO2, RAB12, RAB20, 
RAB43, RNASE7, SCAPER, SLC16A13, SMAGP, 
TECPR2, TGM2, UBC, ZFX
26 12 Cell Death and 
Survival, Cell-to-Cell 
Signaling and Interac-
tion, Cellular Function 
and Maintenance
5.11E-12
The networks were generated through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com). Each 
gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base (IPKB) and overlaid 
onto a global molecular network developed from information contained in the IPKB. Scores, corresponding to degree of enrich-
ment, are negative log of p-values of Fisher test. Genes in bold (focus molecules) are genes that are represented by top hit 
SNPs in our genome-wide association study of placental abruption.
date gene studies. The only other GWAS by our 
group [14] identified several novel and candi-
date SNPs that are potentially related to PA 
risk. Several of the top SNPs identified in the 
previous study were significantly associated 
with PA risk, at the P <0.05 level, in our expand-
ed sample. These included SNPs in the DGKB 
(chr7:14154194, P-value=6e-04), SMAD2 (chr- 
18:453999981, P-value=2e-04), and MIR17HG 
(rs4773624, P-value=0.003). In addition, a 
SNP in previously identified candidate gene, 
the CETP gene (rs891144, P-value=6.94E-04), 
was among the top hits in the GWAS analyses 
in our study. Ali et al. [31], in their case-control 
study among women with idiopathic PA, placen-
ta previa, and normal pregnancies, found that 
the B2 allele frequency in idiopathic PA was 
higher than its frequency in placenta previa or 
normal pregnancy (P-value <0.05).
The top GWAS hit in our study, rs1238566, is a 
SNP in the FLI-1 gene, a megakaryocyte-specif-
ic transcription factor. The A allele of this SNP is 
weakly (P=0.08) associated with increased 
expression of the FLI-1 gene in lymphoblastoid 
cell lines [32]. Coagulation defects, where 
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megakaryocytes play key roles, such as 
decreased platelets, elevated prothrombin 
time, decreased fibrinogen levels, and elevated 
fibrin split products, have closely been associ-
ated with the clinical events of PA. Therefore, 
the finding that a variation in the FLI-1 gene 
may be associated with PA risk is of high 
significance.
We assessed recombination rates and LD of 
SNPs near putative associated variants identi-
fied in the genome-wide and candidate gene 
association analyses. The regional SNP associ-
ation plots illustrating the complex genetic 
architecture for rs1238566 (from the genome-
wide analysis) and chr3:12440243 (from the 
candidate gene analysis) are shown in Figure 4. 
Other genes in the neighborhood of these 
SNPs, such as the ETS1 gene that has been 
shown to be involved in connective tissue 
metabolism, fibrosis, inflammation, and related 
disease conditions (e.g. SLE), are putative can-
didates as genetic susceptibility factors of PA 
[33, 34].
In pathway analyses of genes represented by 
top hits of the GWAS analyses, lipid metabolism 
and cell signaling networks were identified. 
Dyslipidemia has been associated with a num-
ber of pregnancy complications that include 
preeclampsia, a hypertensive disorder of preg-
nancy that has been closely related to PA [35]. 
Recent evidence also points to lipid-related 
high risk profiles (e.g., higher cholesterol, LDL, 
and lower HDL) for cardiovascular diseases 
among women with history of PA, supporting 
potential risk similarities of PA with other car-
diovascular diseases in the general population 
[36]. However, significant gap remains in our 
understanding of direct relationships between 
lipid abnormalities, or genetic factors that 
underlie these abnormalities and risk of PA. 
Cell signaling which is a broad category that 
encompasses a diverse set of cellular interac-
tions is a critical component of cellular func-
tion. As described in our previous report, and 
supported by current findings, several candi-
dates (such as the SMAD family of genes and 
the DPP6 gene) in cell-signaling pathways may 
have roles in risk of PA [14]. Further research 
into the extent of their roles and the specific 
signaling pathways that are important is 
warranted.
Several mechanisms may explain why variation 
in mitochondrial biogenesis and oxidative phos-
phorylation related genes might contribute to 
mitochondrial dysfunction and PA. Oxidative 
Figure 4. Regional SNP association plot for the top GWAS SNP rs1238566 and candidate SNP chr3:12440243. Estimated local 
recombination rate and –log10 P-values are plotted in blue on the right and left side of the y-axis, respectively. The genomic 
position is shown on the x-axis. Linkage disequilibrium (r2) of a nearby SNP with the index SNP is shown by purple color.
Table 5. Genetic risk score (GRS) and risk of placental abruption











Intervals <10.9 10.9-13.9 14.0-17.0 ≥17.1
Cases, n (%) 49 (10) 45 (10) 140 (30) 236 (50)
Controls, n (%) 142 (30) 69 (15) 138 (29) 124 (26)
OR (95% CI)** 1.00 1.85 (1.12-3.05) 2.90 (1.97-4.33) 5.45 (3.68-8.06) <0.001
Candidate Gene Analysis
Intervals <8 8-8.9 9-9.9 ≥10
Cases, Number (%) 34 (8) 72 (17) 113 (27) 197 (47)
Controls, Number (%) 58 (14) 80 (19) 103 (25) 175 (42)
OR (95% CI)** 1.00 1.55 (0.91-2.64) 1.88 (1.14-3.11) 1.91 (1.20-3.06) 0.01
*GRS computed from 14 SNPs that are top hits from GWAS analyses, and 11 SNPs that are top hits from the candidate gene 
association analyses. **Odds ratios (and 95% confidence intervals) from logistic regression models adjusted for age, sex, and 
population admixture, linear trend P-values.
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stress-induced damage to mitochondrial struc-
tural elements (e.g., lipid membranes) may 
alter mitochondrial gene expression and pro-
mote a deficiency in oxidative phosphorylation 
[37]. Variation in genes related to mitochondrial 
biogenesis may confer susceptibility to damage 
from oxidative stress and variation in genes 
related to oxidative phosphorylation may 
accentuate the deficiency in oxidative phos-
phorylation that results from mitochondrial dys-
function. In the current candidate gene associ-
ation analyses, we found that several SNPs in 
mitochondrial biogenesis (e.g., CAMK2B, 
NR1H3, PPARG, PRKCA, and THRB) and oxida-
tive phosphorylation (e.g., COX5A, and NDUF 
family of genes) related genes are associated 
with risk of PA. Of these, the PPARG and NDUF 
genes were represented by several SNPs. The 
role of PPARG in placentation has been well 
documented [38, 39]. Interestingly, investiga-
tors have put forth thesis indicating that PPARG 
mediates defective placentation (e.g., inhibi-
tion of trophoblast invasion) that results from 
oxidized LDL in cytotrophoblasts of villous and 
extravillous cells [40]. The NDUF gene, encod-
ing the NADH:ubiquinone oxidoreductase pro-
tein, is part of the enzyme complex in the elec-
tron transport chain of mitochondria [41]. While 
the gene and other genes in the family, and 
their variants have been reported in relation to 
other diseases such as AIDS and prostate can-
cer, to our knowledge, no previous study report-
ed variation in this gene in relation to pregnan-
cy complications [42, 43]. Future studies are 
needed to further explore the role of these sets 
of genes in placentation and PA risk.
GRS based on risk allele genotypes of multiple 
SNPs have been used to summarize genetic 
effects among ensemble of markers that do 
not individually achieve significance in associa-
tion studies [44]. In the current study, both GRS 
computed using top hits of SNPs in the GWAS 
and candidate gene analyses were significantly 
associated with risk of PA. One potential limita-
tion of our GRS-based analyses is the fact that 
we used the same data set for training and 
testing. We conducted cross-validation to 
assess the utility of the GRS [45]. Based on 
that test, we observed that the GWAS based 
GRS had an agreement of 64% with the true 
value (PA cases and controls), while the candi-
date-based GRS score has an agreement of 
55% with the true value. However, sensitivity of 
the GWAS-based GRS score was 82% while 
sensitivity of the candidate-based GRS score 
was 71%. Specificity for the two scores, respec-
tively, was 46% and 34%. A significant overesti-
mation of the PA risk was observed. Based on 
previous suggestions by Thomsen et al. [45], 
the validity of our GRS scores should be exam-
ined in other study populations with different 
indices of diseases.
Other limitations of our study merit consider-
ation. Although our study is the largest to date 
on the topic, we may still be underpowered to 
detect significant associations between genet-
ic variations, particularly less common varia-
tions, and risk of PA. This is particularly true for 
small effect sizes. Potential misclassifications 
of sub-clinical PA may further limit our study 
power. Absence of a replication cohort and lack 
of follow-up functional studies are other limita-
tions of our study. Finally, generalizability of our 
findings should be confirmed by studies that 
are conducted in study populations that differ 
in genetic and other characteristics from ours.
Some strengths of our study deserve mention. 
We used multiple (GWAS, pathway, candidate, 
and GRS) analytic approaches to examine asso-
ciations between genetic susceptibility and risk 
of PA. These different approaches provided us 
with the opportunity to identify genetic risk that 
may be associated with PA, a multigenic com-
plex disorder. In our candidate gene analyses, 
we have specifically drawn attention to mito-
chondrial biogenesis and oxidative phosphory-
lation, an emerging little explored pathway that 
is significant in placental pathophysiology, 
pregnancy complications, and outcomes. Our 
study was conducted among a high-risk under-
investigated study population and relatively 
less problem of population stratification are 
other strengths of the study.
In summary, our study suggests that integrat-
ing multiple genomic analytical strategies pro-
vides opportunities for identifying novel biologi-
cal pathways for exploring the underlying 
molecular mechanisms for PA. In addition, our 
GRS analyses support the promise of using 
genetic association studies in PA risk predic-
tion. Future studies that involve larger discov-
ery and replication samples, functional follow-
up of confirmed PA-associated variants, and 
risk-prediction, among others, may enhance 
efforts to understand PA pathomechanisms 
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and facilitate the development of prevention 
strategies.
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SNPs implicated in Mitochondrial Biogenesis
CAMK2B 25 0.0012 chr7:44221640 A 0.02044 4.40 7 934 chr7:44221639 1.00 1.00
CAMK2D 2 0.4804 rs4141007 G 0.03557 1.20 4 941 rs4834348 0.32 0.01
CAMK4 1 0.0669 rs11748647 A 0.1865 1.20 5 940 N/A N/A N/A
CREB1 1 0.1239 rs17811997 C 0.01501 1.80 2 938 N/A N/A N/A
NR1H3 23 0.0381 chr11:47237338 A 0.1594 1.30 11 918 N/A N/A N/A
PPARA 2 0.0338 rs4253728 A 0.05573 0.64 22 941 rs4253776 0.90 0.34
PPARG 127 0.0047 chr3:12309555 A 0.1573 1.40 3 938 N/A N/A N/A
PPARGC1A 1 0.1436 rs10018239 G 0.07299 0.77 4 932 N/A N/A N/A
PPARGC1B 1 0.3404 rs26124 A 0.3953 1.10 5 940 N/A N/A N/A
PRKCA 65 0.0215 chr17:61730083 A 0.01086 0.30 17 939 N/A N/A N/A
SP1 1 0.1670 rs7131938 A 0.2204 0.85 12 941 N/A N/A N/A
THRB 10 0.0017 rs7609948 A 0.2341 1.40 3 925 rs17014418 1.00 0.17
TRNT1 1 0.1627 rs7629889 A 0.2755 0.87 3 941 N/A N/A N/A
SNPs implicated in Oxidative Phosphorylation
COX5A 17 0.0461 chr15:73013139 G 0.1357 0.76 15 941 N/A N/A N/A
COX10 2 0.1680 rs17616591 G 0.06043 0.76 17 941 rs12943936 1.00 0.18
COX4I1 1 0.2943 rs2733954 A 0.4066 0.91 16 940 N/A N/A N/A
COX7A2 1 0.4326 rs436898 A 0.1412 0.90 6 939 N/A N/A N/A
CPX7A2L 1 0.3998 rs8162 G 0.2234 0.91 2 937 N/A N/A N/A
COX7B2 2 0.0557 rs1512128 A 0.02786 1.70 4 941 rs4395475 0.69 0.01
LRPPRC 9 0.2314 rs4953042 G 0.3859 1.10 2 938 rs6723119 1.00 0.33
NDUFA10 2 0.0710 rs4149549 A 0.2058 1.20 2 929 rs6437237 1.00 0.22
NDUFA12 5 0.0180 rs7300945 G 0.4036 0.80 12 937 rs11107847 1.00 0.42
NDUFA3 2 0.2959 rs7253859 G 0.02066 1.40 19 940 N/A N/A N/A
NDUFB1 1 0.1511 rs6575231 A 0.4582 0.87 14 941 N/A N/A N/A
NDUFC1 1 0.1830 rs12642647 G 0.07453 0.79 4 941 N/A N/A N/A
NDUFC2_
KCTD14
1 0.0125 rs627297 C 0.1663 0.74 11 940 N/A N/A N/A
NDUFS4 2 0.2217 rs256108 G 0.1692 0.86 5 941 rs2637030 1.00 0.56
PPA2 3 0.2656 rs2074396 A 0.3345 1.10 4 940 rs959086 1.00 0.24
SDHB 3 0.0997 rs2235928 G 0.3531 1.20 1 936 rs2647209 0.40 0.00
TSFM 1 0.2785 rs10783848 A 0.4137 1.11 12 941 N/A N/A N/A
TUFM 4 0.3121 chr16:28761497 A 0.2199 0.90 16 935 N/A N/A N/A
NDUFS3 3 0.2675 chr11:47562003 A 0.2552 1.10 11 937 N/A N/A N/A
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Supplementary Table 2. Single nucleotide polymorphisms included in the genetic risk score (GRS) 
analyses
Gene SNP Minor Allele MAF Odds Ratio P-value
GWAS based GRS
FLI1 rs1238566 G 0.3366 1.46 (1.21-1.77) 1.00E-04
CAP2 rs1320995 C 0.3482 0.69 (0.56-0.83) 2.00E-04
CC2D2A rs10939621 A 0.2421 0.71 (0.57-0.88) 0.002
LOC647946 rs10502722 C 0.4144 0.70 (0.59-0.85) 1.00E-04
TECPR2 rs4900536 G 0.3462 0.70 (0.57-0.83) 2.00E-04
SIRT1 rs10997860 G 0.4597 1.33 (1.11-1.59) 0.002
ADCY5 chr3:124618938 A 0.4559 1.41 (1.16-1.68) 2.00E-04
DPP6 rs2024366 G 0.1409 1.65 (1.27-2.17) 3.00E-04
PHLDB2 rs6808720 A 0.4427 1.36 (1.12-1.61) 9.00E-04
PLIN3 rs3760950 A 0.3789 1.42 (1.18-1.72) 4.00E-04
EML2 chr19:50840077 G 0.2717 1.43 (1.17-1.73) 4.00E-04
CAP2 rs1320994 G 0.3681 0.71 (0.58-0.85) 4.00E-04
NCOR2 rs12582168 G 0.4263 0.72 (0.61-0.87) 5.00E-04
EDIL3 rs350477 A 0.2448 0.67 (0.55-0.56) 6.00E-04
Candidate gene analyses based GRS
CAMK2B chr7:44221559 G 0.2652 0.77 (0.63-0.95) 0.013
NR1H3 chr11:47237338 A 0.1594 1.31 (1.02-1.68) 0.038
PPARG chr3:12309555 A 0.1573 1.44 (1.11-1.84) 0.005
PPARG chr3:12336385 A 0.4687 1.19 (0.99-1.44) 0.067
PPARG chr3:12440243 A 0.1834 1.30 (1.02-1.62) 0.027
PRKCA chr17:61738444 G 0.2898 0.82 (0.67-1.02) 0.059
THRB rs9814223 A 0.3479 0.83 (0.68-0.99) 0.048
COX5A chr15:73013139 G 0.1357 0.76 (0.59-1.00) 0.046
NDUFA10 rs4149549 A 0.2058 1.23 (0.98-1.54) 0.071
NDUFA12 rs11107847 A 0.4292 0.83 (0.70-1.01) 0.051
NDUFC2_KCTD14 rs627297 C 0.1663 0.74 (0.59-0.95) 0.013
